FIND-CKD and FLOW: Benefits Across Heterogeneous Patient Populations

Finerenon significantly slowed the decline in kidney function in non-diabetic adults with chronic kidney disease (CKD) and also reduced the risk of cardiovascular complications —according to recently published data from the FIND-CKD study. Recent analyses of the FLOW study showed that semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and CKD. These study findings offer another ray of hope for people living with CKD.